{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T01:42:47Z","timestamp":1780105367684,"version":"3.54.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.coph.2013.10.002","type":"journal-article","created":{"date-parts":[[2013,11,13]],"date-time":"2013-11-13T03:33:43Z","timestamp":1384313623000},"page":"18-22","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Preventing cognitive decline in preclinical Alzheimer's disease"],"prefix":"10.1016","volume":"14","author":[{"given":"Wim J","family":"Riedel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2013.10.002_bib0005","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00002093-200304000-00002","article-title":"The magnitude of dementia occurrence in the world","volume":"17","author":"Wimo","year":"2003","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.1016\/j.coph.2013.10.002_bib0010","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.mcna.2013.01.002","article-title":"Clinical trials in predementia stages of Alzheimer disease","volume":"97","author":"Pillai","year":"2013","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.coph.2013.10.002_bib0015","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/NEN.0b013e31825018f7","article-title":"Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature","volume":"71","author":"Nelson","year":"2012","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.coph.2013.10.002_bib0020","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1001\/archneur.58.12.1985","article-title":"Current concepts in mild cognitive impairment","volume":"58","author":"Petersen","year":"2001","journal-title":"Arch Neurol"},{"key":"10.1016\/j.coph.2013.10.002_bib0025","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.neurobiolaging.2010.04.007","article-title":"Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging","volume":"31","author":"Rowe","year":"2010","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.coph.2013.10.002_bib0030","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.coph.2013.10.002_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurobiolaging.2011.02.018","article-title":"Preclinical AD Workgroup staging: pathological correlates and potential challenges","volume":"33","author":"Jicha","year":"2012","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.coph.2013.10.002_bib0040","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","article-title":"Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study","volume":"12","author":"Villemagne","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.coph.2013.10.002_sbref0045","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/ana.22628","article-title":"An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease","volume":"71","author":"Jack","year":"2012","journal-title":"Ann Neurol"},{"key":"10.1016\/j.coph.2013.10.002_sbref0050","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S1474-4422(13)70194-7","article-title":"Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study","volume":"12","author":"Vos","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.coph.2013.10.002_bib0055","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/S1474-4422(10)70223-4","article-title":"Revising the definition of Alzheimer's disease: a new lexicon","volume":"9","author":"Dubois","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.coph.2013.10.002_bib0060","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1212\/WNL.0b013e3182563bbe","article-title":"Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease","volume":"78","author":"Knopman","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.coph.2013.10.002_bib0065","series-title":"Guidance for Industry: Alzheimer's Disease: Developing Drugs for the Treatment of Early Stage Disease","author":"Center for Drug Evaluation and Research (CDER)","year":"2013"},{"key":"10.1016\/j.coph.2013.10.002_bib0070","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1056\/NEJMp1302513","article-title":"Regulatory innovation and drug development for early-stage Alzheimer's disease","volume":"368","author":"Kozauer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2013.10.002_bib0075","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1017\/S1355617701755105","article-title":"Preclinical prediction of AD using neuropsychological tests","volume":"7","author":"Albert","year":"2001","journal-title":"J Int Neuropsychol Soc"},{"key":"10.1016\/j.coph.2013.10.002_bib0080","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1001\/archneurol.2009.272","article-title":"Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition","volume":"66","author":"Storandt","year":"2009","journal-title":"Arch Neurol"},{"key":"10.1016\/j.coph.2013.10.002_bib0085","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/00002093-199700112-00003","article-title":"Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study","volume":"11","author":"Mohs","year":"1997","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.1016\/j.coph.2013.10.002_bib0090","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1001\/archneur.64.9.1323","article-title":"A neuropsychological test battery for use in Alzheimer disease clinical trials","volume":"64","author":"Harrison","year":"2007","journal-title":"Arch Neurol"},{"key":"10.1016\/j.coph.2013.10.002_sbref0095","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jalz.2011.11.002","article-title":"Alzheimer's Disease Neuroimaging I: rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer's disease clinical trials","volume":"9","author":"Cedarbaum","year":"2013","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.coph.2013.10.002_bib0100","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1212\/WNL.0b013e31828ab35d","article-title":"Meta-analysis of amyloid-cognition relations in cognitively normal older adults","volume":"80","author":"Hedden","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.coph.2013.10.002_bib0105","doi-asserted-by":"crossref","first-page":"861","DOI":"10.3233\/JAD-122170","article-title":"Decline in cognitive function over 18 months in healthy older adults with high amyloid-beta","volume":"34","author":"Ellis","year":"2013","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.coph.2013.10.002_sbref0110","doi-asserted-by":"crossref","first-page":"675","DOI":"10.3233\/JAD-2012-121516","article-title":"Rapid decline in episodic memory in healthy older adults with high amyloid-beta","volume":"33","author":"Lim","year":"2013","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.coph.2013.10.002_bib0115","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/ana.22248","article-title":"Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease","volume":"69","author":"Villemagne","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.coph.2013.10.002_bib0120","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1212\/WNL.0b013e31826e9ae6","article-title":"Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults","volume":"79","author":"Lim","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.coph.2013.10.002_sbref0125","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000342116","article-title":"Applicability of the CANTAB-PAL computerized memory test in identifying amnestic mild cognitive impairment and Alzheimer's disease","volume":"34","author":"Junkkila","year":"2012","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1016\/j.coph.2013.10.002_sbref0130","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.neuron.2012.06.022","article-title":"Fractionating human intelligence","volume":"76","author":"Hampshire","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.coph.2013.10.002_bib0135","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.158","article-title":"High-throughput cognitive assessment using BrainTest.org: examining cognitive control in a family cohort","author":"Sabb","year":"2013","journal-title":"Brain Behav"},{"key":"10.1016\/j.coph.2013.10.002_bib0140","doi-asserted-by":"crossref","first-page":"e57476","DOI":"10.1371\/journal.pone.0057476","article-title":"Internet-based screening for dementia risk","volume":"8","author":"Brandt","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.coph.2013.10.002_bib0145","series-title":"Improving Services and Support for People with Dementia","author":"National Audit Office","year":"2007"},{"key":"10.1016\/j.coph.2013.10.002_sbref0150","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jalz.2010.07.001","article-title":"An economic evaluation of early assessment for Alzheimer's disease in the United Kingdom","volume":"8","author":"Getsios","year":"2012","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.coph.2013.10.002_bib0155","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1016\/j.jalz.2013.05.1769","article-title":"The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception","volume":"9","author":"Weiner","year":"2013","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.coph.2013.10.002_bib0160","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1017\/S1041610209009405","article-title":"The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease","volume":"21","author":"Ellis","year":"2009","journal-title":"Int Psychogeriatr"},{"key":"10.1016\/j.coph.2013.10.002_bib0165","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1159\/000135644","article-title":"Development of screening guidelines and clinical criteria for predementia Alzheimer's disease. The DESCRIPA Study","volume":"30","author":"Visser","year":"2008","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.coph.2013.10.002_bib0170","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1126\/science.1228541","article-title":"Preventing Alzheimer's disease","volume":"337","author":"Selkoe","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.coph.2013.10.002_bib0175","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/01.pra.0000400265.37666.4e","article-title":"Phase I trials: from traditional to newer approaches part II","volume":"17","author":"Macaluso","year":"2011","journal-title":"J Psychiatr Pract"},{"key":"10.1016\/j.coph.2013.10.002_bib0180","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/01.pra.0000398413.44244.f8","article-title":"Phase I trials: from traditional to newer approaches. Part I","volume":"17","author":"Macaluso","year":"2011","journal-title":"J Psychiatr Pract"},{"key":"10.1016\/j.coph.2013.10.002_bib0185","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/clpt.2009.68","article-title":"I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy","volume":"86","author":"Barker","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.coph.2013.10.002_bib0190","series-title":"Prevention of Alzheimer's Disease \u2014 What Will It Take?","article-title":"Building an adaptive trial in AD: challenges and solutions","author":"Sperling","year":"2013"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489213001999?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489213001999?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T14:04:20Z","timestamp":1564668260000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489213001999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":38,"alternative-id":["S1471489213001999"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2013.10.002","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]}}}